Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

28/01/2021 Institutional visit to the Elena Renewable Gas Plant in Parc de l'Alba 12/01/2021 2021: the Alba synchrotron begins its mutation 30/12/2020 The Park has a new Urban Development Master Plan 29/11/2020 The director of Parc de l'Alba, Pere Solà, academic director of the new Postgraduate Course in Urban Planning and Health at the UPC School 18/11/2020 Catalan minister Ramon Tremosa visits the ALBA synchrotron and announces the creation of a public-private investment fund to improve knowledge transfer 03/11/2020 Catalonia, at the forefront of Europe in life sciences and health; the Alba synchrotron contributes to this leadership
1 2 3 4 5 6 7 8